The goal of this study was to investigate the anti-tumor efficacy of HER2 peptide pulsed DC1 vaccine in combination with PD-1/PD-L1 blockade and HER2 targeted therapy in a preclinical model of HER2+ breast cancer. Here, ERBB2 is linked to neoplasm.